Wound Repair

Tissue Repair is a clinical-stage biotechnology company focused on developing and commercializing advanced wound healing agents. The company's core technology is based on its proprietary biologically active pharmaceutical ingredient (API), Glucoprime, a yeast-derived beta-glucan that stimulates the body's natural wound repair pathways by mimicking a yeast infection. Its lead drug candidate, TR987, is currently in Phase 3 clinical trials for the treatment of chronic venous leg ulcers (VLU). Additionally, the company has commercialized TR Pro+, a topical hydrogel for post-procedure recovery in the aesthetic market. Tissue Repair aims to address significant unmet needs in the chronic wound and aesthetic dermatology sectors.